* If you want to update the article please login/register
To determine the reliability of the questionnaire by comparing the results of the experiments between General population subjects and a group of hypothyroidism sufferers in a treatment nau00efve subjects group with hypothyroidism. Male and female patients between the ages of 18 years and 65 years Willing to sign the Subject Authorization Form Arm 2: Subjects who are newly diagnosed Hypothyroidism and are taking medication are naefve*. Thyroid Stimulating Hormone > 4. 5 Milli international units per litre, which was used to diagnose Hypothyroidism by a doctor and diagnosed with hypothyroidism by a physician and diagnosed with hypothyroidism within 2 weeks from the time of the survey. Individuals under the age of 18 years or more than 65 years old, with an onset of hypothyroid disease diagnosed on a naive basis lab and clinical diagnosis within the last two weeks Exclusion criteria for subjects Arm 1: Patients from the general population who are younger than 18 years of age and over 65 years old. Two hundred patients of Hypothyroidism are being treated nau00efve with equal distribution of males and females, according to Arm 2: Two hundred female patients of Hypothyroidism are treated equally across both males and females. Arm 2: Sixteen participants are returned to hypothyroidism who are newly diagnosed patients of Hypothyroidism, with equal distribution of males and females. Arm 2: One hundred patients from the general population are treated in the same number of males and females and females are na's nau00efence to their hypothyroidismoefence in females and females, with equal distribution of males, with equal distribution of hypothyroidismau00efve Arm 2: Sixteen patients are treated a's, and females.
Source link: https://clinicaltrials.gov/ct2/show/NCT04784208
Methodology The investigators will perform a double-blind, placebo-controlled clinical trial in which eligible veterans from SCH and LT4 are 1:1 randomized to continue LT4 or switch to placebo, with eligible veterans diagnosed with SCH and LT4 diagnosed with SCH and LT4 randomized to either continue LT4 or change to placebo. At the conclusion of the clinical trial, the investigators will determine the acceptability of LT4 discontinuation through semi-structured qualitative interviews with participants and LT4 prescribers.
Source link: https://clinicaltrials.gov/ct2/show/NCT04288115
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions